search
Back to results

Investigating the Role of the Polyol Pathway in the Central Nervous System

Primary Purpose

Hyperglycemia

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Brain MRS during hyperglycemic clamp
Analysis of Metabolites in cerebrospinal fluid
Sponsored by
Yale University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Hyperglycemia

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Type 2 DM with HbA1C treated with metformin, sulfonylurea, insulin, or combination OR age-matched, non-diabetic obese (BMI > 30 kg/m^2) OR age-matched lean, healthy control subjects (BMI < 25 kg/m^2)
  • Age 18-55
  • BMI 18-45 kg/m^2

Exclusion Criteria:

  • Creatinine > 1.5 mg/dL
  • Hgb < 10 mg/dL
  • ALT > 2.5 x ULN
  • Untreated thyroid disease
  • Uncontrolled Hypertension
  • Known Neurological Disorders
  • Untreated Psychiatric Disorders
  • Malignancy
  • Bleeding Disorders
  • Smoking
  • Current or recent steroid use in last 3 months
  • Illicit drug use
  • Pregnancy, actively seeking pregnancy, or breastfeeding
  • Inability to enter MRI/MRS

Sites / Locations

  • Yale University

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Active Comparator

Arm Label

Subjects with Type 2 Diabetes

Non-Diabetic Obese

Lean, healthy control subjects

Arm Description

Type 2 DM subjects with HbA1C > 7.5% treated with metformin, sulfonylurea, insulin or combination

Age-matched, non-diabetic obese (BMI > 30 kg/m^3) individuals

Age-matched, lean, healthy control subjects (BMI < 25 kkg/m^3)

Outcomes

Primary Outcome Measures

Metabolite Measurements by MRS
metabolite levels will be measured by MRS

Secondary Outcome Measures

Hunger Ratings
Hunger will be measured using a visual analog scale
Satiety Ratings
Satiety will be measured using a visual analog scale
Cognitive State
Participants will be asked to complete basic cognitive testing using the mini-mental status exam and the Montreal cognitive assessment

Full Information

First Posted
October 20, 2014
Last Updated
August 15, 2022
Sponsor
Yale University
Collaborators
American Diabetes Association
search

1. Study Identification

Unique Protocol Identification Number
NCT02272556
Brief Title
Investigating the Role of the Polyol Pathway in the Central Nervous System
Official Title
Investigating the Role of Polyol Pathway in the Central Nervous System
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Completed
Study Start Date
February 2015 (undefined)
Primary Completion Date
May 18, 2022 (Actual)
Study Completion Date
May 18, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yale University
Collaborators
American Diabetes Association

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Patients will undergo magnetic resonance spectroscopy (MRS) scanning to noninvasively measure intracerebral and plasma metabolite levels at baseline and following 2 and 4 hours of hyperglycemia. Subjects will also undergo a lumbar puncture at a separate occasion to assess cerebrospinal fluid levels of metabolites.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hyperglycemia

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
138 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Subjects with Type 2 Diabetes
Arm Type
Active Comparator
Arm Description
Type 2 DM subjects with HbA1C > 7.5% treated with metformin, sulfonylurea, insulin or combination
Arm Title
Non-Diabetic Obese
Arm Type
Active Comparator
Arm Description
Age-matched, non-diabetic obese (BMI > 30 kg/m^3) individuals
Arm Title
Lean, healthy control subjects
Arm Type
Active Comparator
Arm Description
Age-matched, lean, healthy control subjects (BMI < 25 kkg/m^3)
Intervention Type
Other
Intervention Name(s)
Brain MRS during hyperglycemic clamp
Intervention Description
All patients will undergo brain MRS at baseline and following 2 and 4 hours of hyperglycemia using the clamp technique
Intervention Type
Other
Intervention Name(s)
Analysis of Metabolites in cerebrospinal fluid
Intervention Description
All patients will have the option to undergo a lumbar puncture for analysis of metabolites in cerebrospinal fluid
Primary Outcome Measure Information:
Title
Metabolite Measurements by MRS
Description
metabolite levels will be measured by MRS
Time Frame
4 hours post hyperglycemia
Secondary Outcome Measure Information:
Title
Hunger Ratings
Description
Hunger will be measured using a visual analog scale
Time Frame
4 hours post hyperglycemia
Title
Satiety Ratings
Description
Satiety will be measured using a visual analog scale
Time Frame
4 hours post hyperglycemia
Title
Cognitive State
Description
Participants will be asked to complete basic cognitive testing using the mini-mental status exam and the Montreal cognitive assessment
Time Frame
4 hours post hyperglycemia
Other Pre-specified Outcome Measures:
Title
Cerebrospinal fluid cell count
Description
Metabolite levels will be measure in collected spinal fluid
Time Frame
2 weeks post MRS testing
Title
protein levels
Description
Metabolite levels will be measure in collected spinal fluid
Time Frame
2 weeks post MRS testing

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Type 2 DM with HbA1C treated with metformin, sulfonylurea, insulin, or combination OR age-matched, non-diabetic obese (BMI > 30 kg/m^2) OR age-matched lean, healthy control subjects (BMI < 25 kg/m^2) Age 18-55 BMI 18-45 kg/m^2 Exclusion Criteria: Creatinine > 1.5 mg/dL Hgb < 10 mg/dL ALT > 2.5 x ULN Untreated thyroid disease Uncontrolled Hypertension Known Neurological Disorders Untreated Psychiatric Disorders Malignancy Bleeding Disorders Smoking Current or recent steroid use in last 3 months Illicit drug use Pregnancy, actively seeking pregnancy, or breastfeeding Inability to enter MRI/MRS
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert Sherwin, MD
Organizational Affiliation
Yale University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Yale University
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06519
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Investigating the Role of the Polyol Pathway in the Central Nervous System

We'll reach out to this number within 24 hrs